Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991217833> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W1991217833 endingPage "S110" @default.
- W1991217833 startingPage "S110" @default.
- W1991217833 abstract "Idursulfase beta (Hunterase®) has been used for enzyme replacement therapy (ERT) of patients with mucopolysaccharidosis II (MPS II, Hunter syndrome) aged 6 years or older since 2012 in Korea. The objective of this study was to evaluate the safety and efficacy of ERT with idursulfase beta in Hunter syndrome children younger than 6 years. This study was a 52-week, single center, single arm, open-label clinical trial (NCT01645189). Idursulfase beta (0.5 mg/kg/week) was administered intravenously for 52 weeks. The primary endpoint was safety assessed by adverse events (AEs). Secondary endpoints included vital signs, physical examination, ECG, laboratory tests, anti-idursulfase antibodies, and efficacy represented by changes in urinary glycosaminoglycan (GAG) at week 53 from baseline. In addition, growth indices and developmental milestones (Denver II test) were evaluated as exploratory variables. All six patients experienced at least one AE. A total of 109 AEs were reported. One patient experienced a serious AE (hospitalization due to gastroenteritis) that was considered not to be treatment related. One patient (16.7%) experienced infusion-related adverse drug reactions (ADRs), developing urticaria six times and a cough five times. There were no serious ADRs and no clinically significant changes in vital signs, physical exam, laboratory parameters, or ECG. Of the six patients, four (66.7%) showed anti-idursulfase antibodies and neutralizing antibodies on at least one occasion during the study. At week 53, urinary GAG was significantly reduced by − 35.1 ± 30.6 mg GAG/g creatine from baseline (P = 0.038). This study indicates that the safety and efficacy of idursulfase beta are similar to those reported in Hunter syndrome patients aged 6 years or older." @default.
- W1991217833 created "2016-06-24" @default.
- W1991217833 creator A5023196934 @default.
- W1991217833 creator A5036401265 @default.
- W1991217833 creator A5067211207 @default.
- W1991217833 creator A5069342446 @default.
- W1991217833 date "2015-02-01" @default.
- W1991217833 modified "2023-09-26" @default.
- W1991217833 title "Safety of caregiver administration of enzyme replacement therapy in the home setting" @default.
- W1991217833 doi "https://doi.org/10.1016/j.ymgme.2014.12.249" @default.
- W1991217833 hasPublicationYear "2015" @default.
- W1991217833 type Work @default.
- W1991217833 sameAs 1991217833 @default.
- W1991217833 citedByCount "0" @default.
- W1991217833 crossrefType "journal-article" @default.
- W1991217833 hasAuthorship W1991217833A5023196934 @default.
- W1991217833 hasAuthorship W1991217833A5036401265 @default.
- W1991217833 hasAuthorship W1991217833A5067211207 @default.
- W1991217833 hasAuthorship W1991217833A5069342446 @default.
- W1991217833 hasConcept C126322002 @default.
- W1991217833 hasConcept C141071460 @default.
- W1991217833 hasConcept C187212893 @default.
- W1991217833 hasConcept C197934379 @default.
- W1991217833 hasConcept C203092338 @default.
- W1991217833 hasConcept C2776225084 @default.
- W1991217833 hasConcept C2776890885 @default.
- W1991217833 hasConcept C2779134260 @default.
- W1991217833 hasConcept C2779416428 @default.
- W1991217833 hasConcept C2779969927 @default.
- W1991217833 hasConcept C2910638406 @default.
- W1991217833 hasConcept C527108885 @default.
- W1991217833 hasConcept C535046627 @default.
- W1991217833 hasConcept C71924100 @default.
- W1991217833 hasConceptScore W1991217833C126322002 @default.
- W1991217833 hasConceptScore W1991217833C141071460 @default.
- W1991217833 hasConceptScore W1991217833C187212893 @default.
- W1991217833 hasConceptScore W1991217833C197934379 @default.
- W1991217833 hasConceptScore W1991217833C203092338 @default.
- W1991217833 hasConceptScore W1991217833C2776225084 @default.
- W1991217833 hasConceptScore W1991217833C2776890885 @default.
- W1991217833 hasConceptScore W1991217833C2779134260 @default.
- W1991217833 hasConceptScore W1991217833C2779416428 @default.
- W1991217833 hasConceptScore W1991217833C2779969927 @default.
- W1991217833 hasConceptScore W1991217833C2910638406 @default.
- W1991217833 hasConceptScore W1991217833C527108885 @default.
- W1991217833 hasConceptScore W1991217833C535046627 @default.
- W1991217833 hasConceptScore W1991217833C71924100 @default.
- W1991217833 hasIssue "2" @default.
- W1991217833 hasLocation W19912178331 @default.
- W1991217833 hasOpenAccess W1991217833 @default.
- W1991217833 hasPrimaryLocation W19912178331 @default.
- W1991217833 hasRelatedWork W1572142576 @default.
- W1991217833 hasRelatedWork W1584581471 @default.
- W1991217833 hasRelatedWork W1699619364 @default.
- W1991217833 hasRelatedWork W2031326286 @default.
- W1991217833 hasRelatedWork W2117500144 @default.
- W1991217833 hasRelatedWork W2143063409 @default.
- W1991217833 hasRelatedWork W2149588051 @default.
- W1991217833 hasRelatedWork W2404010182 @default.
- W1991217833 hasRelatedWork W3082276934 @default.
- W1991217833 hasRelatedWork W4200610496 @default.
- W1991217833 hasVolume "114" @default.
- W1991217833 isParatext "false" @default.
- W1991217833 isRetracted "false" @default.
- W1991217833 magId "1991217833" @default.
- W1991217833 workType "article" @default.